All News

2021

March

Media Release / Mar 30, 2021

Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis

Read More
Media Release / Mar 30, 2021

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

Read More
Media Release / Mar 23, 2021

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Read More
Media Release / Mar 22, 2021

Novartis appoints Karen Hale as Chief Legal Officer

Read More
Media Release / Mar 15, 2021

New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment

Read More
Media Release / Mar 09, 2021

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

Read More
Media Release / Mar 05, 2021

Novartis announces change to the Executive Committee

Read More
Media Release / Mar 04, 2021

Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate

Read More
Media Release / Mar 02, 2021

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Read More

February

Media Release / Feb 26, 2021

Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More